"How to Better Understand PRP From A to Z"

FDA To Crack Down On Stem Cell And Gene Therapy Clinics

Over the past couple of years, the FDA (Food and Drug Administration) has noticed a surge in the number of cell and gene therapy products that are entering early development – or investigational new drug applications (INDs) as they are properly known.

In January this year, the FDA released a statement that announced their intention to advance the development of effective cell and gene therapies in a safe manner.

New innovations have been described as being the main driver in cell and gene therapy development. The new FDA policies are designed to encourage product development that’s done efficiently.

The key areas that the FDA will focus on are:

  • Making sure that the FDA has sufficient review capacity
  • The promotion of expedited programs
  • The issues of effective new guidelines
  • Ensuring that cell and gene therapy clinics comply with FDA regulations

The FDA Has Issued Some Concerns Over Cell and Gene Therapy Products and Services

The two authors of the statement – Dr. Scott Gottlieb, M.D. and Dr. Peter Marks, M.D., Ph.D. – used the message to raise concerns over some cell and gene therapy product developers and service providers operating outside FDA regulations. Such flaunting of FDA regulations is unsafe for the public, as products developed without meeting regulatory compliance could actually be harmful.

In order to hopefully safeguard the public, the FDA has announced that it will be taking steps to create near-term enforcement actions against cell and gene therapy product developers and service providers who operate without bothering to comply with FDA regulations.

Cell and gene therapy is an important and ever-improving sector of medicine as developed therapies can help treat and even cure many typically untreatable diseases. With the help of the FDA, it is hoped that innovation in these fields will be encouraged to the benefit of the public, but only if such therapies are developed in a safe, secure and regulatory manner.

Here at the Michigan Center for Regenerative Medicine, we completely support the FDA and their commitment to public safety. We operate fully in compliance with FDA regulations and we are committed to serving our patients and clients as best we can. In addition, we welcome any additional oversight by the FDA to ensure regenerative medicine clinics around the country are run properly and with the patient’s best interests in mind at all times. If you would like to learn more about we can do for you, please reach out to our team today at (248) 216-1008 or use our online contact form.

S h o p